Invest now

Eris Lifesciences Profit & Loss Annual

BSE: 540596 | NSE: ERIS | ISIN: INE406M01024 | Sector: Biotechnology & Drugs
1,162.60 +15.70 (1.37%)Updated : 08 Oct 2026
Research on
Fiscal Period2026202520242023
Period End DateMar 26Mar 25Mar 24Mar 23
Total Operating Expense 2,306.012,190.961,514.781,263.49
Other Net 3.589.215.571.72
Diluted Weighted Average Shares 13.6913.6313.6213.62
Gain( Loss)on Saleof Assets -0.04-0.92-2.14-2.01
Depreciation/ Amortization 279.50315.46182.61117.09
Operating Income 823.41702.68494.37421.66
Net Income 619.52351.84391.98382.16
Income Availableto Com Excl Extra Ord 619.52351.84391.98382.16
Other Operating Expenses Total 41.9920.1822.0926.92
Net Income Before Taxes 638.54488.87431.24404.64
Minority Interest -27.99-22.83-5.078.00
Net Income After Taxes 647.51374.67397.05374.16
Income Availableto Com Incl Extra Ord 619.52351.84391.98382.16
Costof Revenue Total 831.10745.18399.68362.78
Gross Profit 2,298.322,148.461,609.461,322.37
Interest Inc( Exp) Net- Non- Op Total -188.41-222.10-66.56-16.74
Unusual Expense( Income) 17.24-0.02-0.00
Diluted Net Income 619.52351.84391.98382.16
Provisionfor Income Taxes -8.97114.2034.1930.48
period Type ----
Net Income Before Extra Items 619.52351.84391.98382.16
Total Revenue 3,129.422,893.642,009.141,685.15
period Length 12.0012.0012.0012.00
Revenue 3,129.422,893.642,009.141,685.15
Selling/ General/ Admin Expenses Total 1,131.851,107.72904.68750.60
Diluted Normalized EPS 46.0825.8728.9328.20
Research Development 4.332.445.726.10
Diluted EPS Excluding Extra Ord Items 45.2625.8128.7928.07
DPS- Common Stock Primary Issue -7.350.007.35
*All figures in crores except per share values
Recommended For You
Trending Stocks
1,035.00+40.00(4.02%)
1,246.00+17.00(1.38%)
11,400.00-549.00 (-4.59%)